A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

Ningning Liu, Chunjiao Liu, Xiaofen Li, Siyan Liao, Wenbin Song, Changshan Yang, Chong Zhao, Hongbiao Huang, Lixia Guan, Peiquan Zhang, Shouting Liu, Xianliang Hua, Xin Chen, Ping Zhou, Xiaoying Lan, Songgang Yi, Shunqing Wang, Xuejun Wang, Q. Ping Dou, Jinbao Liu

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been reported that metal complexes, such as copper complexes, inhibit tumor proteasome. However, the involved mechanism of action has not been fully characterized. Here we report that (i) copper pyrithione (CuPT), an alternative to tributyltin for antifouling paint biocides, inhibits the ubiquitin-proteasome system (UPS) via targeting both 19S proteasome-specific DUBs and 20S proteolytic peptidases with a mechanism distinct from that of the FDA-approved proteasome inhibitor bortezomib; (ii) CuPT potently inhibits proteasome-specific UCHL5 and USP14 activities; (iii) CuPT inhibits tumor growth in vivo and induces cytotoxicity in vitro and ex vivo. This study uncovers a novel class of dual inhibitors of DUBs and proteasome and suggests a potential clinical strategy for cancer therapy.

Original languageEnglish (US)
Article number5240
JournalScientific reports
Volume4
DOIs
StatePublished - Jun 10 2014

Fingerprint

Proteasome Inhibitors
Proteasome Endopeptidase Complex
Peptide Hydrolases
Growth
Neoplasms
Paint
Disinfectants
Coordination Complexes
Therapeutics
Ubiquitin
Multiple Myeloma
Deubiquitinating Enzymes
Copper

ASJC Scopus subject areas

  • General

Cite this

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. / Liu, Ningning; Liu, Chunjiao; Li, Xiaofen; Liao, Siyan; Song, Wenbin; Yang, Changshan; Zhao, Chong; Huang, Hongbiao; Guan, Lixia; Zhang, Peiquan; Liu, Shouting; Hua, Xianliang; Chen, Xin; Zhou, Ping; Lan, Xiaoying; Yi, Songgang; Wang, Shunqing; Wang, Xuejun; Dou, Q. Ping; Liu, Jinbao.

In: Scientific reports, Vol. 4, 5240, 10.06.2014.

Research output: Contribution to journalArticle

Liu, N, Liu, C, Li, X, Liao, S, Song, W, Yang, C, Zhao, C, Huang, H, Guan, L, Zhang, P, Liu, S, Hua, X, Chen, X, Zhou, P, Lan, X, Yi, S, Wang, S, Wang, X, Dou, QP & Liu, J 2014, 'A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases', Scientific reports, vol. 4, 5240. https://doi.org/10.1038/srep05240
Liu, Ningning ; Liu, Chunjiao ; Li, Xiaofen ; Liao, Siyan ; Song, Wenbin ; Yang, Changshan ; Zhao, Chong ; Huang, Hongbiao ; Guan, Lixia ; Zhang, Peiquan ; Liu, Shouting ; Hua, Xianliang ; Chen, Xin ; Zhou, Ping ; Lan, Xiaoying ; Yi, Songgang ; Wang, Shunqing ; Wang, Xuejun ; Dou, Q. Ping ; Liu, Jinbao. / A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. In: Scientific reports. 2014 ; Vol. 4.
@article{4b97cf26b6194436b9e81dfdf5ef6d2f,
title = "A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases",
abstract = "The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been reported that metal complexes, such as copper complexes, inhibit tumor proteasome. However, the involved mechanism of action has not been fully characterized. Here we report that (i) copper pyrithione (CuPT), an alternative to tributyltin for antifouling paint biocides, inhibits the ubiquitin-proteasome system (UPS) via targeting both 19S proteasome-specific DUBs and 20S proteolytic peptidases with a mechanism distinct from that of the FDA-approved proteasome inhibitor bortezomib; (ii) CuPT potently inhibits proteasome-specific UCHL5 and USP14 activities; (iii) CuPT inhibits tumor growth in vivo and induces cytotoxicity in vitro and ex vivo. This study uncovers a novel class of dual inhibitors of DUBs and proteasome and suggests a potential clinical strategy for cancer therapy.",
author = "Ningning Liu and Chunjiao Liu and Xiaofen Li and Siyan Liao and Wenbin Song and Changshan Yang and Chong Zhao and Hongbiao Huang and Lixia Guan and Peiquan Zhang and Shouting Liu and Xianliang Hua and Xin Chen and Ping Zhou and Xiaoying Lan and Songgang Yi and Shunqing Wang and Xuejun Wang and Dou, {Q. Ping} and Jinbao Liu",
year = "2014",
month = "6",
day = "10",
doi = "10.1038/srep05240",
language = "English (US)",
volume = "4",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

AU - Liu, Ningning

AU - Liu, Chunjiao

AU - Li, Xiaofen

AU - Liao, Siyan

AU - Song, Wenbin

AU - Yang, Changshan

AU - Zhao, Chong

AU - Huang, Hongbiao

AU - Guan, Lixia

AU - Zhang, Peiquan

AU - Liu, Shouting

AU - Hua, Xianliang

AU - Chen, Xin

AU - Zhou, Ping

AU - Lan, Xiaoying

AU - Yi, Songgang

AU - Wang, Shunqing

AU - Wang, Xuejun

AU - Dou, Q. Ping

AU - Liu, Jinbao

PY - 2014/6/10

Y1 - 2014/6/10

N2 - The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been reported that metal complexes, such as copper complexes, inhibit tumor proteasome. However, the involved mechanism of action has not been fully characterized. Here we report that (i) copper pyrithione (CuPT), an alternative to tributyltin for antifouling paint biocides, inhibits the ubiquitin-proteasome system (UPS) via targeting both 19S proteasome-specific DUBs and 20S proteolytic peptidases with a mechanism distinct from that of the FDA-approved proteasome inhibitor bortezomib; (ii) CuPT potently inhibits proteasome-specific UCHL5 and USP14 activities; (iii) CuPT inhibits tumor growth in vivo and induces cytotoxicity in vitro and ex vivo. This study uncovers a novel class of dual inhibitors of DUBs and proteasome and suggests a potential clinical strategy for cancer therapy.

AB - The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been reported that metal complexes, such as copper complexes, inhibit tumor proteasome. However, the involved mechanism of action has not been fully characterized. Here we report that (i) copper pyrithione (CuPT), an alternative to tributyltin for antifouling paint biocides, inhibits the ubiquitin-proteasome system (UPS) via targeting both 19S proteasome-specific DUBs and 20S proteolytic peptidases with a mechanism distinct from that of the FDA-approved proteasome inhibitor bortezomib; (ii) CuPT potently inhibits proteasome-specific UCHL5 and USP14 activities; (iii) CuPT inhibits tumor growth in vivo and induces cytotoxicity in vitro and ex vivo. This study uncovers a novel class of dual inhibitors of DUBs and proteasome and suggests a potential clinical strategy for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84902257060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902257060&partnerID=8YFLogxK

U2 - 10.1038/srep05240

DO - 10.1038/srep05240

M3 - Article

C2 - 24912524

AN - SCOPUS:84902257060

VL - 4

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 5240

ER -